SPX 6,124.35 ▲ 0.47%DJI 44,210.18 ▼ 0.12%CCMP 19,875.02 ▲ 0.72%SX5E 5,231.77 ▲ 0.24%UKX 8,402.11 ▼ 0.22%NKY 39,870.50 ▲ 0.78%EURUSD 1.0842 ▼ 0.19%USGG10YR 4.31 ▲ 0.94%CL1 71.82 ▼ 0.88%XAU 2,685.40 ▲ 0.42%XBT 97,250.00 ▲ 1.93%SPX 6,124.35 ▲ 0.47%DJI 44,210.18 ▼ 0.12%CCMP 19,875.02 ▲ 0.72%SX5E 5,231.77 ▲ 0.24%UKX 8,402.11 ▼ 0.22%NKY 39,870.50 ▲ 0.78%EURUSD 1.0842 ▼ 0.19%USGG10YR 4.31 ▲ 0.94%CL1 71.82 ▼ 0.88%XAU 2,685.40 ▲ 0.42%XBT 97,250.00 ▲ 1.93%
 

← Persons Index

Thomas Struengmann & family
Rank #323 · Healthcare

Thomas Struengmann & family

Pharmaceuticals · Germany

Net worth$10.5B
Today−$22M
7 days−$238K
30 days−$454M

Net worth, last 30 days

Low $10.5BHigh $11.0B

Biography

Thomas Struengmann and twin brother Andreas were early backers of German firm BioNTech, which partnered with Pfizer to make a vaccine for Covid-19.

The brothers cofounded generic drugmaker Hexal in 1986 and sold it to Novartis in 2005 for some $7 billion.

The brothers invest in biotech, pharma, life sciences and healthcare companies through their Zug, Switzerland-based investment firm, Santo Holding.

In 2008, they established a neuroscience research center in Frankfurt named after their father, Ernst Struengmann.

Did you know

After obtaining a business degree from the University of Augsburg, Thomas worked as a marketing manager for Schering-Plough.

Like his brother, an identical twin, he is said to be an accomplished golfer and likes to ski. He reportedly collects modern art and Swiss watches.

Holdings

CompanyTickerSharesValue
BioNTech Sponsored ADRBNTX-US50,640,000$4.1B
Formycon AGFYB-DE2,124,000$30M
Private assets & other$6.3B

Public holdings ≈ $4.2B. Holdings may include options and overlap between rows.